Key Highlights
- Dr. Elizabeth H. Z. Thompson appointed as Executive Vice President, Head of Research and Development at Acadia Pharmaceuticals.
- Brings extensive experience from Amgen and Horizon Therapeutics, significantly contributing to advancements in rare disease and central nervous system disorders.
- Acadia aims for long-term growth with two commercial products and a robust pipeline focusing on rare disease and central nervous system disorders.
Source: Business Wire
Notable Quotes
- “Liz is a preeminent drug research and development leader… Her leadership will be instrumental as we continue to advance our early and late stage assets,” – Steve Davis, CEO at Acadia
- “With two commercial products on the market and a strong pipeline… we are poised for long term growth,” – Dr. Elizabeth H. Z. Thompson, Executive Vice President, Head of Research and Development at Acadia Pharmaceuticals Inc
SoHC's Take
Acadia Pharmaceuticals Inc. embarks on a new chapter with the addition of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson’s appointment reflects Acadia’s commitment to leadership and innovation, bringing a wealth of experience from her tenure at companies like Amgen and Horizon Therapeutics. Her expertise in advancing first-in-class therapies aligns with Acadia’s mission to address high unmet needs in rare diseases and central nervous system disorders. With a solid pipeline and commercial products poised for impact, Acadia is strategically positioned for sustained growth. This leadership enhancement underscores the company’s dedication to advancing breakthroughs in neuroscience, promising a brighter future for patients and the broader healthcare landscape.
